<code id='E0364E1BE3'></code><style id='E0364E1BE3'></style>
      • <acronym id='E0364E1BE3'></acronym>
      <center id='E0364E1BE3'><center id='E0364E1BE3'><tfoot id='E0364E1BE3'></tfoot></center><abbr id='E0364E1BE3'><dir id='E0364E1BE3'><tfoot id='E0364E1BE3'></tfoot><noframes id='E0364E1BE3'>
      • <optgroup id='E0364E1BE3'><strike id='E0364E1BE3'><sup id='E0364E1BE3'></sup></strike><code id='E0364E1BE3'></code></optgroup>
        5. <b id='E0364E1BE3'><label id='E0364E1BE3'><select id='E0364E1BE3'><dt id='E0364E1BE3'><span id='E0364E1BE3'></span></dt></select></label></b><u id='E0364E1BE3'></u>
          <i id='E0364E1BE3'><strike id='E0364E1BE3'><tt id='E0364E1BE3'><pre id='E0364E1BE3'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-02 03:07:30 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：888
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:
          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.
          advertisement
          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          HHS leader on health, climate change and biopharma emissions
                                
                            
          Next article：  
                                      
                                          As demand for Covid shots wanes, Moderna seeks its next success
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles